7 unknown, 4 not yet recruiting, 2 recruiting, 1 active not recruiting. 14 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Unknown 7, Not yet recruiting 4, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow PD-1: new trials by email Literature Review of PD-1 trials Research Report on PD-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab - Hepatocellular Carcinoma (HCC), Immunotherapy | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 47 | 2025-08-20 | 2025-08-17 |
| A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma Radical surgery, TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706) - Hepatocellular Carcinoma, Immunotherapy | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 48 | 2025-08-11 | 2025-08-20 |
| PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) PD-1inhibitor, radiotherapy - HNSCC, PD-1 | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 50 | 2025-08-01 | 2025-07-29 |
| Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）, Maintenance treatment (after 3 months): fruquintinib+PD-1 - Gastric Adenocarcinoma, GEJ Adenocarcinoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 55 | 2025-03-31 | 2025-03-21 |
| Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery, Traditional surgery - HNSCC, PD-1 | Phase 2 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 60 | 2024-12-15 | 2025-12-05 |
| LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer LM-108 antibody and sintilimab, LM-108 antibody and sintilimab and chemotherapy - NSCLC, PD-1 | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 50 | 2024-01-12 | 2024-06-28 |
| Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) PD-1 with chemotherapy, upright surgery - Oral Cancer, PD-1 | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 40 | 2023-09-01 | 2023-11-14 |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
| 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses - HNSCC, Oral Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 192 | 2023-04-04 | 2023-09-07 |
| A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) F520, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer, NSCLC | Phase 2 | Unknown | Shandong New Time Pharmaceutical Co., LTD | 84 | 2023-03-01 | 2023-02-24 |
| A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study Tislelizumab - Head and Neck Cancer, Radiation | Phase 2 | Unknown | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 38 | 2021-04-01 | 2021-03-24 |
| Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction PD-1inhibitor - PD-1, Neoadjuvant Chemoradiotherapy | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 32 | 2021-03-30 | 2024-02-09 |
| PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC PD-1 plus Dasatinib - NSCLC Stage IV, ARID1A | Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2020-03-01 | 2020-02-25 |
| Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ PD-1 - PD-1, Chemoradiotherapy | Phase 1 / Phase 2 | Unknown | Peking University | 45 | 2019-08-26 | 2019-08-20 |
Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Mouth Neoplasms (2) · Head and Neck Neoplasms (1)
Neoplasms (9) · Neoplasms by Site (9) · Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Head and Neck Neoplasms (4) · Carcinoma, Squamous Cell (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Liver Diseases (2) · Liver Neoplasms (2) · Lung Diseases (2)
Carboplatin (2) · Drug Therapy (2) · toripalimab (2) · Bevacizumab (1) · Dasatinib (1) · Paclitaxel (1) · Pemetrexed (1) · RC48 antibody (1) · Radiotherapy (1) · disitamab vedotin (1) · lenvatinib (1) · sintilimab (1) · tislelizumab (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · Anhui Provincial Hospital (1) · Peking University (1) · RenJi Hospital (1) · Ruijin Hospital (1) · Shandong New Time Pharmaceutical Co., LTD (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · The Affiliated Hospital of Qingdao University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (11)
Chunxia Su, Phd (1) · Haige Chen (1) · Xuehao Wang (1) · Yongheng Li, MD (1) · Yongxiang Xia (1) · Ziyu Li, MD (1)